From soft-tissue to bone: Clinical presentation of fibrodysplasia ossificans progressiva (FOP)
Biosimilars: an option to alleviate the heavy burden of immune-mediated inflammatory diseases
Clinical value beyond price alone: biosimilars improve patient access to treatment
Clinical value beyond price alone: anti-TNF biosimilars enable early treatment
Long-term topical management of psoriasis: the road ahead
Over the horizon: early stage trials for NASH
Phase II trials and stem cell therapies
The next global epidemic
The latest treatments in NASH
The future of organ transplantation
Complications of stem cell transplants
Treating rejection in organ transplants
Challenges in transplant organ rejection
Biologic efficacy for complications associated with moderate-to-severe psoriasis
Moderate-to-severe psoriasis: treatment for young women
Migraine treatments: On the horizon
An independent review of current treatments for migraine
Migraine: The forgotten epidemic?
NEW: Moderate to Severe Asthma Learning Zone launches on Medthority.com
Senolytics: Can we treat age-related diseases with a single drug
Long-term disease control in Psoriasis: announcing a new project
Senolytics: an emerging therapeutic for the prevention and treatment of cardiovascular disease
Targeted therapies in triple negative breast cancer
Targeted therapies in HER2 negative breast cancer
Targeted therapies in HER2 positive breast cancer
Breast Cancer- Targeted therapies
World Congress of Dermatology 2019 - A new ERA for global Dermatology
Opioids - Over the horizon
Opioids: The war on drugs
Opioids: the future and challenging the epidemic
Moderate-to-severe psoriasis: the disease burden and unmet needs in different patient groups
Replacement therapies for opioid drugs in pain treatment
Microbiomes: is there nothing that they can't do?
Shaken not stirred your bacteriophage cocktail
From Acne to Immunotherapy: new applications for FMT (Faecal Microbiota Transplantation)
Part Four | Obesity, Type 2 diabetes and cardiovascular disease: Finding the magic bullet
Part Three | Next generation obesity therapies
Part two | New hopes for treatment in the global obesity epidemic
Part One | The effects of obesity and the links to diabetes and cardiovascular disease: now and in the future
Key findings from the SWIPE study
COPD experts tackle key topics in our latest Q&A
Your guide to IBD novel treatments and assessment tools
Immobility and sleep disruption in the ICU - Latest recommendations
UPDATE: Urticaria e-learning new modules & symposia highlights
Unravelling the microbiome - health through happy communities
Psoriasis Knowledge Centre relaunches on Medthority.com
Atopic Dermatitis Knowledge Centre launched on Medthority.com
Reformulation of postnatal haemorrhage prophylaxis could save thousands in lower income countries
Medical cannabis - a novel approach to pain control
Accredited CME: The future of urticaria - advances in CSU research - launched to Medthority.com
New inflammatory bowel disease (IBD) Knowledge Centre
New rare disease platform launched for Hunter Syndrome
New publication digest and infographic for Cardiologists.
Genetic variation and drug efficacy - could this pave the way for personalised medicines?
Neue Informationsmaterialien in deutscher Sprache zum Management von Schmerzen, Agitation und Delir auf der Intensivstation (in Zusammenarbeit mit Orion Pharma)
New: Symposium videos & presentations for immunologists, dermatologists and allergists
Magnetic nanoparticles could help rejuvenate damaged hearts
New findings may pave the way for novel HIV drugs
Adoptive T cell therapy, advanced melanoma and survival
Appetite and the brain - white matter integrity to blame?
Vitamin D in pregnancy - is it any good?
How close are we to a disease-modifying treatment for Alzheimer’s?
Japan's aging population and Alzheimer's
Focus on Primary Care - helping GPs diagnose, manage and treat urticaria
Prof Vincent interview - Defining the eCASH Concept in PAD Management
Inactivity in the elderly increases their cardiovascular risk by 14%
Close social relationships may slow cognitive decline
Type 2 diabetes risk may be increased by statin use in susceptible individuals
Improving non-alcoholic steatohepatitis care – is the finishing line in sight?
Acute myeloid leukaemia: Hope for new treatments
Left ventricular assist devices – A viable therapeutic option for heart failure?
Antibody-drug conjugates (ADCs)
Horizons: a series of opinion & insight articles on disruptive healthcare in practice
The way ahead for cystic fibrosis
Schizophrenia: challenges in a crowded market
Nonalcoholic steatohepatitis: the next global epidemic?
Launch of LAL-Deficiency Knowledge Centre
Latest updates to the Chronic Spontaneous Urticaria Knowledge Centre
Launch of Oral Anticoagulation Reversal Knowledge Centre
SGLT2 Inhibitors: good news for diabetes
Will Glucagon-like peptide-1 agonists dominate the Type 2 Diabetes market?
Launch of Chronic Spontaneous Urticaria CME activity
Launch of new Cystic Fibrosis Knowledge Centre
Launch of new Chronic Lymphocytic Leukaemia CME
Launch of updated Hypogonadism Knowledge Centre
New approaches to anticoagulant therapy
ESOT 2015 speaker slides added to AIKN-IFI
New type 2 diabetes CME activity now available on Medthority.com
ATS 2015 symposium materials added to COPD Knowledge Centre
WCD 2015 videos added to the Chronic Spontaneous Urticaria (CSU) Knowledge Centre
Case studies added to Chronic Spontaneous Urticaria (CSU) Knowledge Centre
New hyperammonaemia resource developed for Medthority.com users
Chronic myelogenous leukaemia: a remarkable success story
Bedwetting resource receives a mobile-friendly transformation
IL-17A treatment section added to Psoriasis Knowledge Centre
Free haemato-oncology report added to AIKN-IFI congresses section
Parkinson's disease: the struggle to control symptoms
Metastatic melanoma: the new immunotherapies
DSMB supports continuation of Phase III trial of bucillamine in COVID-19.
Eli Lilly and Pfizer discontinue the global clinical development program for tanezumab, an investigational nerve growth factor inhibitor.
Tirzepatide is filed at FDA and at EMA to treat type 2 diabetes.
Pivotal phase III trials of MK 8591 + Pifeltro meet endpoints in HIV.
Phase III TRYbeCA-1 trial of Graspa fails to meet primary endpoint in pancreatic cancer.
Retrospective chart review study of Variquel shows bleed control in esophageal variceal hemorrhage.
Phase III MIRROR trial of Krystexxa meets primary endpoint in chronic gout.
Phase III trial of Dupixent shows efficacy in eosinophilic esophagitis.
Moderna announces positive top line data from phase II/III study of COVID-19 vaccine in children 6 to 11 years.
Imfinzi plus chemotherapy significantly improved overall survival in 1st-line advanced biliary tract cancer.
Novartis presents top-line results for CANOPY-1 phase III study support further evaluation of canakinumab in lung cancer.
Galera Therapeutics announces results of phase III ROMAN trial of avasopasem for radiotherapy-induced severe oral mucositis.
bluebird bio to withdraw marketing of Skysona gene therapy in Europe.
Azurity Pharma acquires Arbor Pharma
FDA approves Susvimo for age-related macular degeneration.- Genentech/Roche
Pepaxto withdrawn from market in US.- Oncopeptides
FDA issues Emergency Use Authorization for a booster dose of the JNJ 78436735 COVID 19 vaccine for adults aged 18 and older.- Johnson & Johnson
FDA approves Ventana PD-L1 (SP263) assay for non-small cell lung cancer detection.- Roche
Phase III ECZTRA 6 trial of Adtralza meets its primary endpoints at 16 weeks for atopic dermatitis.- LEO Pharma
Phase III SOLSTICE trial of Lonsurf fails to meet primary endpoint in colorectal cancer.- Servier
EU approves Keytruda plus chemo for metastatic triple-negative breast cancer.- Merck Inc
Two phase III studies of Xiaflex show efficacy in Peyronie's disease.- Endo International
Baxter and bioMérieux announce CE Mark for NEPHROCLEAR CCL14 test to predict persistent severe acute kidney injury.
Positive pivotal Phase III PRIME2 trial reports on Dupixent in adults with uncontrolled prurigo nodularis
Phase III trial of Comirnaty shows efficacy as booster for COVID-19.
FDA approves Dupixent as add-on treatment for moderate-to-severe asthma.
EU approves Opdivo and chemo for HER2-negative gastric, gastroesophageal junction or oesophageal adenocarcinoma.
Respiratory Syncytial Virus (RSV) in Adults
Chronic Kidney Disease Learning Zone
Molecular diagnostics for RET inhibition in NSCLC and thyroid cancers
Hidradenitis suppurativa (HS) Learning Zone
Multiple Sclerosis (MS) Learning Zone
Food Allergy Learning Zone
Atopic Dermatitis Learning Zone
Cardiovascular Metabolism Learning Zone
Major depressive disorder and treatment-resistant depression
Inflammatory Bowel Disease Learning Zone
Transplantation Learning Zone
Innovations in MS care to improve individual disease management
Diagnosis and management of primary hyperoxaluria type 1
Improving treatment options for childhood psoriasis
CDK4/6 inhibitors in breast cancer
Managing Osteoarthritis-associated Pain
Fluid Management Learning Zone
Anticoagulation Therapy for Stroke Prevention
Optimising anti-TNF treatment using biosimilars
Fibrinogen Deficiency in Bleeding Learning Zone
Idiopathic Pulmonary Fibrosis
Oral Anticoagulation Reversal Learning Zone
Psoriasis Learning Zone
Sleep Apnea Learning Zone
Hereditary ATTR Amyloidosis
One Neuroscience and Pain Learning Zone
Acute Hepatic Porphyria Learning Zone
CSU Learning Zone